Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182817-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$69.90
|
|
|
Ab182817-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$349.90
|
|
|
Ab182817-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$899.90
|
|
|
Ab182817-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,439.90
|
|
Purity≥90% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Cevostamab (anti-CD3&FCRL5) - Primary antibody, specific to CD3E & FCRL5, Human IgG1 |
|---|---|
| Synonyms | BXMAS1 antibody | CD307 antigen antibody | CD307e antibody | Fc receptor homolog 5 antibody | Fc receptor like 5 antibody | Fc receptor-like protein 5 antibody | FcR-like protein 5 antibody | FcRH5 antibody | FcRL5 antibody | FCRL5_HUMAN antibody | Immuno |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | CD3: The CD3 complex mediates signal transduction. FCRL5: May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells. |
| Host species | Human |
| Specificity | CD3E & FCRL5 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Cevostamab (anti-CD3&FCRL5) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab (anti-CD3&FCRL5) facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.
|
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 146.19 kDa |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2249888-53-5 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Cevostamab (anti-CD3&FCRL5) (Ab182817) - Flow Cytometry
Flow Cytometry analysis of huCD3e-Jurkat cells labelling CD3&FCRL5 (red) with Cevostamab (anti-CD3&FCRL5) (Ab182817) at 1×10⁵ cell/well, with the EC₅₀ is 729.0 ng/mL.
Cevostamab (anti-CD3&FCRL5) (Ab182817) - SEC
The purity of Cevostamab (anti-CD3&FCRL5) (Ab182817) is more than 95% verified by HPLC.